<DOC>
	<DOCNO>NCT02172170</DOCNO>
	<brief_summary>Study investigate safety , tolerability , pharmacokinetics pharmacodynamics single rise oral dos BI 10773 healthy male subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Rising Oral Doses BI 10773 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age ≥ 18 Age ≤ 50 year 3 . BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Any finding medical examination include ( ( blood pressure ( BP ) , pulse rate ( PR ) , 12lead electrocardiogram ( ECG ) ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 60 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance 19 . Inability comply dietary regimen trial site 20 . A marked baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) ; 21 . A history additional risk factor torsade de pointes ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) ; Exclusion criterion specific study : 22 . Elevated urinary glucose level screen ( &gt; 15 mg/dl ; &gt; 0.83 mmol/L )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>